Transition to injecting 3,4-methylene-dioxy-pyrovalerone (MDPV) among needle exchange program participants in Hungary

Journal of Psychopharmacology

Volumn 27, Issue 6, 2013, Pages 559-563

  Csák, Róbert ^a   Demetrovics, Zsolt ^b   Rácz, József ^b,c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c Blue Point Outpatient and Prevention Centre   (Hungary)

Author keywords

3,4 methylene dioxy pyrovalerone (MDPV); injecting drug use; needle exchange programs; new psychoactive substances

Indexed keywords

3,4 METHYLENE DIOXYPYROVALERONE; 4' METHYLMETHCATHINONE; AMPHETAMINE; COCAINE; DIAMORPHINE; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONSUMER ATTITUDE; DRUG CHOICE; DRUG USE; FEMALE; HUMAN; HUNGARY; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUBSTANCE ABUSE;

3; 4-METHYLENE-DIOXY-PYROVALERONE (MDPV); INJECTING DRUG USE; NEEDLE EXCHANGE PROGRAMS; NEW PSYCHOACTIVE SUBSTANCES;

ADULT; AMPHETAMINE-RELATED DISORDERS; BENZODIOXOLES; DATA COLLECTION; DESIGNER DRUGS; FEMALE; HEROIN DEPENDENCE; HUMANS; HUNGARY; MALE; NEEDLE-EXCHANGE PROGRAMS; PYRROLIDINES; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84878056847     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113480987     Document Type: Article

References (14)

1. Blue Point (2011) Official report. Available at: http://kekpont.hu/ jelentesek/ (accessed 25 February 2013).
2. Coppola M, Mondola R. 3,4-Methylenedioxypyrovalerone (MDPV): Chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett. 2012 ; 208: 12-15
3. Degenhardt D, Day C, Gilmour S, et al. Patterns of illicit drug use in NSW, Australia following a reduction in heroin supply. Int J Drug Policy. 2005a ; 16: 300-307
4. Degenhardt L, Day C, Hall W, et al. Was an increase in cocaine use among injecting drug users in New South Wales, Australia, accompanied by an increase in violent crime?. BMC Public Health. 2005b ; 5: 40
5. Gerevich J, Bácskai E. Drug use in Hungary: An overview. Int J Addict. 1995 ; 30: 291-303
6. Márványkövi F, Melles K, Légmán A, et al. A kezelésbe jutás akadályai roma és nem roma, kezelésen kívüli intravénás használok körében, Budapesten. Addictologia Hungarica. 2008 ; 7: 205-233
7. Meltzer PC, Butler D, Deschamps R, et al. 1(4Methylphenyl) 2pyrrolidin1ylpentan1one (pyrovalerone) analogues: A promising class of monoamine uptake inhibitors. J Med Chem. 2006 ; 49: 1420-1432
8. 2010 National Report to the EMCDDA. 'Hungary' New developments, trends and in-depth information on selected issues. Budapest: Reitox National Focal Point ; 2010 :
9. 2011 National Report to the EMCDDA. 'Hungary' New developments, trends and in-depth information on selected issues. Budapest: Reitox National Focal Point ; 2011 :
10. 2012 National Report to the EMCDDA. 'Hungary' New developments, trends and in-depth information on selected issues. Budapest: Reitox National Focal Point ; 2012 :
11. Ross S, Peselow E. The neurobiology of addictive disorders. Clin Neuropharmacol. 2009 ; 32: 269-276
12. Spiller HA, Ryan ML, Weston RG, et al. Clinical experience with and analytical confirmation of 'bath salts' and 'legal highs' (synthetic cathinones) in the United States. Clin Toxicol. 2011 ; 49: 499-505
13. Chicago, Illinois: SPSS Inc ; 2006 :
14. Topp L, Day C, Degenhardt L. Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia. Drug Alcohol Depend. 2003 ; 70: 275-286